Cisplatin-Induced Inhibition of p34^cdc2 is Abolished by 5-Fluorouracil

References

• Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Nat Cancer Inst 1993; 85: 95–111.
   PubMedGoogle Scholar
• Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in humanovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923–5.
   PubMed Web of Science ®Google Scholar
• Lewin F, Skog S, Tribukait B, Ringborg U. Effect of com-bined treatment with cisplatin and 5-fluorouracil on the cell growth and cell cycle kinetics of a mouse ascites tumour growing in vivo. In Vivo 1990; 4: 277–82.
   PubMedGoogle Scholar
• Nylen U, Skog S, Lewin F. Absence of misincorporation of pyrimidines in DNA after treatment with a combination of cisplatin (cis-diammine-dichloro-platinum) and 5-fluorouracil of mouse sarcoma cells. Acta Oncol 1996; 35: 229–35.
   Google Scholar
• Lewin F, Ringborg U, Skog S, Tribukait B. The effect of 5-fluorouracil on cis-diammine-dichloroplatinum (II) induced DNA interstrand crosslinking in a mouse ascites tumor grow-ing in vivo. Anti-Cancer Drugs 1995; 6: 465–70.
   PubMedGoogle Scholar
• Coleman TR, Dunphy WG. Cdc2 regulatory factors. Curr Opinion in Cell Biol 1994; 6: 877–82.
   PubMed Web of Science ®Google Scholar
• Draetta G, Beach D. Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement. Cell 1988; 54: 17–26.
   PubMed Web of Science ®Google Scholar
• Pines J, Hunter T. Isolation of a human cyclin cDNA; evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 1989; 58: 833–46.
   PubMed Web of Science ®Google Scholar
• Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1990; 344: 503–8.
   PubMed Web of Science ®Google Scholar
• Lundgren K, Walworth N, Booher R, Dembski M, Kirshner M, Beach D. mikl and weel cooperate in the inhibitory tyrosine phosphorylation of cdc2. Cell 1991; 64: 1111–22.
   PubMed Web of Science ®Google Scholar
• Mueller PR, Coleman TR, Kumagai A, Dunphy WG. Mytl: a membrane-associated inhibitory kinase that phosphorylates cdc2 on both threonine-14 and tyrosine-15. Science 1995; 270: 86–90.
   PubMed Web of Science ®Google Scholar
• Ogg S, Gabrielli B, Piwnica-Worms H. Purification of a serine kinase that associates with and phosphorylates human cdc25C on serine 216. J Biol Chem 1994; 269: 30461–9.
   Google Scholar
• Mailer JL. Biochemistry of cell cycle checkpoints at the G2/M and metaphase/anaphase transitions. Developmental Biol 1994; 5: 183–90.
   Google Scholar
• Hoffmann I, Karsenti E. The role of cdc25C in checkpoints and feedback controls in the eucaryotic cell cycle. J Cell Sci 1994; Suppl 18: 75–9.
   Google Scholar
• Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G. Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J 1993; 12: 53–63.
   Google Scholar
• Lock RB, Ross WE. Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells. Cancer Res 1990; 50: 3761–6.
   PubMed Web of Science ®Google Scholar
• O'Connor PM, Ferris DK, Hoffman I, Jackman J, Draetta G, Kohn KW. Role of the cdc25C phosphatase in G2 arrest induced by nitrogen mustard. Proc Natl Acad Sci USA 1994; 91: 9480–4.
   PubMedGoogle Scholar
• O'Connor PM, Ferris DK, Pagano M, et al. G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem 1993; 268: 8298–308.
   PubMed Web of Science ®Google Scholar
• Yasutake H, Tsuchiya H, Tomita K, Matsunaga T, Nikaido O, Mori T. Inhibitory effect of caffeine on potentially lethal damage repair in cisplatin-treated osteosarcoma cells. Anti-cancer Res 1995; 15: 831–8.
   Google Scholar
• Chu G. Cellular responses to cisplatin. J Biol Chem 1994; 269: 787–90.
   PubMed Web of Science ®Google Scholar
• Nisho K, Fujiwara Y, Miyahara Y, et al. Cis-di-amminedichloroplatinum (II) inhibits p34cdc2 protein kinase in human lung-cancer cells. Int J Cancer 1993; 55: 616–22.
   PubMedGoogle Scholar
• Pinedo HM. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653–64.
   PubMed Web of Science ®Google Scholar
• Skog S, Lewin F, Heiden T, Tribukait B. DNA synthesis after combined treatment with cisplatin and 5-fluorouracil of a mouse tumor growing in vivo. Anti-Cancer Drugs 1994; 5: 83–9.
   PubMedGoogle Scholar
• Ghoshal K, Jacob ST. Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res 1994; 54: 632–6.
   PubMed Web of Science ®Google Scholar
• Skog S, Tribukait B, Sundelius G. Energy metabolism and ATP turnover time during the cell cycle of Ehrlich ascites tumour cells. Explt Cell Res 1982; 141: 23–9.
   Google Scholar
• Castro J, Heiden T, Wang N, Tribukait B. Preparation of cell nuclei from fresh tissues for high-quality DNA flow cytometry. Cytometry 1993; 14: 793–804.
   PubMedGoogle Scholar
• Tuel-Ahlgren L, Jun X, Waddick KG, Jin J, Bolen J, Uckun FM. Role of tyrosin phosphorylation in radiation-in-duced cell cycle-arrest of leukemic B-cell precursors at the G2-M transition checkpoint. Leukemia and Lymphoma 1996; 20: 417–26.
   Google Scholar
• Heald R, McLoughlin M, McKeon F. Human Weel maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 1993; 74: 463–74.
   Google Scholar
• Murray AW. The genetics of cell cycle checkpoints. Cur-rent Opinion Gen Dev 1995; 5: 5–11.
   PubMedGoogle Scholar
• Thiebaut F, Enns R, Howell S. Cisplatin sensitivity corre-lates with its ability to cause cell cycle arrest via a weel kinase-dependent pathway in Scizosaccharomyces pombe. J Cell Physiol 1994; 159: 506–14.
   Google Scholar